<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01440829</url>
  </required_header>
  <id_info>
    <org_study_id>LOLA-TIPS</org_study_id>
    <nct_id>NCT01440829</nct_id>
  </id_info>
  <brief_title>The Effectiveness of L-ornithine-L-aspartate (LOLA) on Plasma Ammonia in Cirrhotic Patients After TIPS</brief_title>
  <official_title>The Effectiveness of L-ornithine-L-aspartate on Plasma Ammonia in Cirrhotic Patients After TIPS Procedure: a Prospective, Randomized, Controlled, Open-label Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Air Force Military Medical University, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Air Force Military Medical University, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the effectiveness of L-ornithine-L-aspartate (LOLA) on&#xD;
      plasma ammonia in cirrhotic patients after Transjugular Intrahepatic Portosystemic Shunt&#xD;
      (TIPS) procedure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with successful TIPS deployment are randomized to LOLA arm and blank control arm.&#xD;
      Plasma ammonia concentrations are measured before TIPS, day 1, day 4 and day 7 after TIPS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma ammonia</measure>
    <time_frame>One week</time_frame>
    <description>The plasma ammonia concentrations of venous blood at the first, fourth and seventh days after TIPS procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of hepatic encephalopathy</measure>
    <time_frame>One week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver function</measure>
    <time_frame>One week</time_frame>
    <description>The liver function (includes PT/INR, APTT, albumin, bilirubin, Child-Pugh score) at the first, fourth and seventh days after TIPS procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychometric tests</measure>
    <time_frame>One week</time_frame>
    <description>The results of the psychometric tests (include number connection test A, number connection test B, digit symbol test, serial dotting test, line tracing test) at the first, fourth and seventh days after TIPS procedure.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Decompensated Cirrhosis</condition>
  <condition>Portal Hypertension</condition>
  <condition>Bleeding Varices</condition>
  <condition>Refractory Ascites</condition>
  <arm_group>
    <arm_group_label>LOLA group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: LOLA (30g per day) for a week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will not be treated with LOLA.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-ornithine-L-aspartate</intervention_name>
    <description>The patients will be treated with LOLA (30g per day) for a week after TIPS procedure.</description>
    <arm_group_label>LOLA group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cirrhotic patients with refractory ascites or at least one episode of variceal&#xD;
             bleeding&#xD;
&#xD;
          -  No active bleeding within 5 days before TIPS&#xD;
&#xD;
          -  Child-Pugh score ≤ 11&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  An age &lt; 18 years or &gt; 65 years&#xD;
&#xD;
          -  With TIPS contraindications&#xD;
&#xD;
          -  Using drugs for hepatic encephalopathy such as neomycin, rifaximin, lactulose,&#xD;
             lactitol or branched-chain amino acid.&#xD;
&#xD;
          -  Intake of psychostimulants, sedatives, antidepressants, benzodiazepines or&#xD;
             benzodiazepine-antagonists&#xD;
&#xD;
          -  Past or present history of hepatic encephalopathy&#xD;
&#xD;
          -  Pregnancy or breast-feeding&#xD;
&#xD;
          -  Hepatic carcinoma and/or other malignancy diseases&#xD;
&#xD;
          -  Sepsis&#xD;
&#xD;
          -  Spontaneous bacterial peritonitis&#xD;
&#xD;
          -  Uncontrollable hypertension&#xD;
&#xD;
          -  Serious cardiac or pulmonary dysfunction&#xD;
&#xD;
          -  Renal failure&#xD;
&#xD;
          -  Portal vein thrombosis&#xD;
&#xD;
          -  History of organ transplantation&#xD;
&#xD;
          -  History of HIV (human immunodeficiency viruses) infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guohong Han, PhD &amp; MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xijing Hospital of Digestive Diseases, Fourth Military Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Xijing Hospital of Digestive Diseases, Fourth Military Medical University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Stauch S, Kircheis G, Adler G, Beckh K, Ditschuneit H, Görtelmeyer R, Hendricks R, Heuser A, Karoff C, Malfertheiner P, Mayer D, Rösch W, Steffens J. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. J Hepatol. 1998 May;28(5):856-64.</citation>
    <PMID>9625322</PMID>
  </reference>
  <reference>
    <citation>Rose C, Michalak A, Rao KV, Quack G, Kircheis G, Butterworth RF. L-ornithine-L-aspartate lowers plasma and cerebrospinal fluid ammonia and prevents brain edema in rats with acute liver failure. Hepatology. 1999 Sep;30(3):636-40.</citation>
    <PMID>10462368</PMID>
  </reference>
  <reference>
    <citation>Rees CJ, Oppong K, Al Mardini H, Hudson M, Record CO. Effect of L-ornithine-L-aspartate on patients with and without TIPS undergoing glutamine challenge: a double blind, placebo controlled trial. Gut. 2000 Oct;47(4):571-4.</citation>
    <PMID>10986219</PMID>
  </reference>
  <reference>
    <citation>Nolte W, Wiltfang J, Schindler C, Münke H, Unterberg K, Zumhasch U, Figulla HR, Werner G, Hartmann H, Ramadori G. Portosystemic hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: clinical, laboratory, psychometric, and electroencephalographic investigations. Hepatology. 1998 Nov;28(5):1215-25.</citation>
    <PMID>9794904</PMID>
  </reference>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>September 21, 2011</study_first_submitted>
  <study_first_submitted_qc>September 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2011</study_first_posted>
  <last_update_submitted>December 18, 2012</last_update_submitted>
  <last_update_submitted_qc>December 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Air Force Military Medical University, China</investigator_affiliation>
    <investigator_full_name>Guohong Han</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Transjugular Intrahepatic Portosystemic Shunt</keyword>
  <keyword>TIPS</keyword>
  <keyword>Liver Cirrhosis</keyword>
  <keyword>LOLA</keyword>
  <keyword>L-ornithine-L-aspartate</keyword>
  <keyword>Refractory Ascites</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Ascites</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>N-Methylaspartate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

